Report : Middle East & Africa Malaria Treatment Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Treatment (Prescription Medications, Vaccines, Diagnostic Tests, and Others), Drug Type (Branded and Generic), Route of Administration (Oral and Parenteral & Intravenous), Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), and End User (Hospitals, Specialty Clinics, Homecare, and Others)
At 3.5% CAGR, the Middle East & Africa Malaria Treatment Market is speculated to be worth US$ 63.02 million by 2028, says Business Market Insights
According to Business Market Insights’ research, the Middle East & Africa malaria treatment market was valued at US$ 51.35 million in 2022 and is expected to reach US$ 63.02 million by 2028, registering a CAGR of 3.5% from 2022 to 2028. Increasing prevalence of malaria and vaccines and government and private sector’s initiatives to raise awareness about malaria are the critical factors attributed to the Middle East & Africa malaria treatment market expansion.
Malaria awareness campaigns help enhance knowledge regarding the disease and improve behaviors promoting health, along with promoting intersectoral collaboration and social support. The WHO coordinates the Global Malaria Programme (GMP) as part of its efforts to control and eradicate malaria. The program is led by the "Global Technical Strategy for Malaria 2016–2030" adopted by the World Health Assembly in May 2015, which was further restructured in 2021. The WHO observes 25 April as World Malaria Day every year to highlight the collective energy and commitment of the malaria communities in uniting around the common objective of freeing from malaria. Several governments are taking initiatives to create awareness and conduct research for the development of new antimalarial drugs and vaccines. Private companies are also engaging in the fight against malaria and investing heavily in R&D activities. For instance, in 2018, Novartis invested more than US$ 100 million to enhance its research and development activities for next-generation treatments by 2023. Governments in countries with a high prevalence of malaria are deploying various strategies to eradicate malaria by improving access to treatment and helping communities in malaria-endemic countries in delivering better healthcare. Several initiatives by governments and private companies to spread awareness about malaria and reinforce malaria eradication efforts are bolstering the Middle East & Africa malaria treatment market growth.
On the contrary, counterfeit antimalarial drugs and subsequent drug resistance hurdles the growth of Middle East & Africa malaria treatment market.
Based on treatment, the Middle East & Africa malaria treatment market is segmented into prescription medications, vaccines, diagnostic tests, and others. The diagnostic tests segment held 41.3% market share in 2022, amassing US$ 21.23 million. It is projected to garner US$ 25.52 million by 2028 to expand at 3.1% CAGR during 2022–2028. Further, prescription medications segment is further categorized into chloroquine phosphate, artemisinin-based combination therapies (ACTs), atovaquone-proguanil, quinine sulfate (qualaquin) with doxycycline, primaquine phosphate, and others.
Based on drug type, the Middle East & Africa malaria treatment market is bifurcated into branded and generic. The generic segment held 57.0% market share in 2022, amassing US$ 29.26 million. It is projected to garner US$ 34.80 million by 2028 to expand at 2.9% CAGR during 2022–2028.
Based on route of administration, the Middle East & Africa malaria treatment market is bifurcated into oral and parenteral & intravenous. The oral segment held 71.9% market share in 2022, amassing US$ 36.91 million. It is projected to garner US$ 44.78 million by 2028 to expand at 3.3% CAGR during 2022–2028.
Based on distribution channel, the Middle East & Africa malaria treatment market is segmented into direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. The direct tender segment held 47.8% market share in 2022, amassing US$ 24.55 million. It is projected to garner US$ 30.25 million by 2028 to expand at 3.5% CAGR during 2022–2028.
Based on end user, the Middle East & Africa malaria treatment market is segmented into hospitals, specialty clinics, homecare, and others. The specialty clinics segment held 42.5% market share in 2022, amassing US$ 21.82 million. It is projected to garner US$ 27.81 million by 2028 to expand at 4.1% CAGR during 2022–2028.
Based on country, the Middle East & Africa malaria treatment market has been categorized into Saudi Arabia, South Africa, the UAE, Nigeria, The Democratic Republic of Congo, United Republic of Tanzania, Mozambique, Uganda, Ghana, Burkina Faso, Kenya, Zambia, and the Rest of Middle East & Africa. Our regional analysis states that Saudi Arabia captured 29.1% market share in 2022. It was assessed at US$ 14.93 million in 2022 and is likely to hit US$ 17.72 million by 2028, exhibiting a CAGR of 2.9% during the forecast period.
Key players dominating the Middle East & Africa malaria treatment market are AdvaCare Pharma USA LLC, Cipla Ltd, GSK Plc, Lupin Ltd, Novartis AG, Sanofi SA, Sun Pharmaceutical Industries Ltd, Viatris Inc, and Zydus Healthcare Ltd among others.
- In July 2020, Novartis advanced another novel malaria therapy, INE963, a fast-acting long-lasting antimalarial with an entirely new mechanism of action. INE963 is in early clinical trials. It was developed in collaboration with MMV and received the organization’s “Project of the Year” award in 2020.
Contact Us
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: sam@businessmarketinsights.com